REMARKS

The independent claims have been amended to require substitutions in at least positions 250 and 428 as described in the specification at e.g., p. 18, lines 29-32. The independent claims have also been amended to clarify that the amino acid positions recited in the claim are determined by the EU numbering system as described at, e.g., p. 2, line 6 of the specification.

In response to the species election mailed October 13, 2005, applicants elect species without traverse as follows:

- (1) Daclizumab as the unmodified antibody.
- (2) Positions 250 and 428 as a specific set of positions.
- (3) Glutamine and leucine as the specific substitutions.
- (4) The SEQ ID NOS. for the heavy chain of modified Daclizumab are SEQ ID NOS. 119-128. The Daclizumab light chain is SEQ ID NO:118. SEQ ID NOS. 122 and 127 are IgG1 and IgG2 isotypes of Daclizumab in which positions 250 and 428 are occupied by glutamine and leucine respectively. It is not entirely clear whether the Examiner wishes applicants to elect the SEQ ID NOS. of a specific modified antibody. If so, applicants elect a modified antibody comprising a light chain designated SEQ ID NO:118 and a heavy chain designated SEQ ID NO:122. As to the cell line, applicants elect murine myeloma cell line Sp2/0, and as to the vectors applicants elect pVg1 for the heavy chain and pVk for the light.

Claims 1-8, 12 and 14-18 read on the elected species. Following the election of species, applicants note that MPEP 809.02(c) requires a "complete action on the merits of all claims readable on the species."

Appl. No. 10/822,300 Amdt. dated November 11, 2005 Preliminary Amendment

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,

Joe Liebeschuetz Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: 650-326-2400 Fax: 415-576-0300

JOL:sjj 60633507 v1